January 24, 2017
Short: Van Herk Investments announces 10.07% Shareholding in Ablynx
Van Herk Investments B.V. has become owner of more than 10% of Ablynx as it has crossed the 10% threshold and now…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
January 24, 2017
Vectura starts with testing asthma drug/device combination for children
Vectura Group is moving on with researching and testing its VR647, a drug/device combination to treat asthma in children for the US market.
January 24, 2017
Advanced Oncotherapy to take “appropriate action” against Sinophi Healthcare
Advanced Oncotherapy said on Tuesday it will “appropriately” deal with a UK company Sinophi Healthcare, which invests in and manages hospitals in China, because it wanted to drop purchase orders made two years ago.
January 24, 2017
ImmuPharma appoints new adviser
ImmuPharma has appointed Northland Capital Partners as its Nominated Adviser and sole broker with immediate effect. ImmuPharma is a pharmaceutical…
January 23, 2017
Swedish Oasmia targets $16B worth US animal health care market
A swedish oncology company Oasmia Pharmaceutical AB, which works on finding cancer cures for animals and humans, said it would move its veterinary assets to the United States.
January 23, 2017
BD’s PleurX cleared for recurrent pleural effusions in USA
BD (Becton, Dickinson) has received the U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of PleurX catheter system in certain problems like heart failure.
January 23, 2017
Stada names new executive board member
STADA Arzneimittel AG has named Dr. Barthold Piening as a full Member of the Executive Board with effect from July 1, 2017.
January 23, 2017
Alliance Pharma reduces net debt, doubles revenue
Alliance Pharma’s revenue for 2016, driven by the acquisition of ex-Sinclair products in December 2015, could be more than double compared to the previous year.
January 23, 2017
Oxford Biodynamics in licencing deal with Singapor’s EpiFit
Oxford BioDynamics (OBD) has entered into a pilot development agreement with EpiFit PTE. LTD., (EpiFit), a new Singapore based company, to identify epigenetic biomarkers to evaluate predispositions, variations and responses in healthy volunteers undergoing fitness programmes conducted by EpiFit.
January 23, 2017
Consort in equity raise by Atlas Genetics, funds subsidiary Bespak
Consort Medical, a single source drug and delivery device company, has participated in a further equity raise by Atlas Genetics Ltd.